Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6871 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6869 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2017-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6c514632674c8e2ef2092f745709fac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_416c00f07ed283dcea90eb1031575e4f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e266cedb1a1f20bc5727c6c7b29722a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049d8575eeee9d2b92b49101ff899111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d77074601364bcb6700fa4a334e43e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb460245ae88888bb1b95f443d5465d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ef3417e1eaa859a23e17afa8d3d7ae1 |
publicationDate |
2019-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2017331361-A1 |
titleOfInvention |
Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof |
abstract |
The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2 -expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2 -targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo. |
priorityDate |
2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |